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and Momir Polenakovic1Abstract
Despite the overall success of prostate specific antigen (PSA) in screening and detection of prostate cancer (PCa),
its use has been limited due to the lack of specificity. The principal driving goal currently within PCa research is to
identify non-invasive biomarker(s) for early detection of aggressive tumors with greater sensitivity and specificity
than PSA. In this study, we focused on identification of non-invasive biomarkers in urine with higher specificity than
PSA. We tested urine samples from PCa and benign prostatic hyperplasia (BPH) patients by 2-D DIGE coupled with
MS and bioinformatics analysis. Statistically significant (p < 0.05), 1.8 fold variation or more in abundance, showed
41 spots, corresponding to 23 proteins. The Ingenuity Pathway Analysis showed significant association with the
Acute Phase Response Signaling pathway. Nine proteins with differential abundances were included in this pathway:
AMBP, APOA1, FGA, FGG, HP, ITIH4, SERPINA1, TF and TTR. The expression pattern of 4 acute phase response proteins
differed from the defined expression in the canonical pathway. The urine levels of TF, AMPB and HP were measured
by immunoturbidimetry in an independent validation set. The concentration of AMPB in urine was significantly higher
in PCa while levels of TF and HP were opposite (p < 0.05). The AUC for the individual proteins ranged from 0.723 to
0.754. The combination of HP and AMBP yielded the highest accuracy (AUC = 0.848), greater than PSA. The proposed
biomarker set is quickly quantifiable and economical with potential to improve the sensitivity and specificity of
PCa detection.
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The introduction of prostate specific antigen (PSA) as a
biomarker for prostate cancer (PCa) screening and de-
tection has transformed the management of this disease
[1-3]. Despite the overall success of the PSA blood test,
its use has been limited due to the lack of specificity,
especially in patients with total serum PSA levels in a
range of 2–10 ng/ml. Various nonmalignant processes
such as benign prostatic hyperplasia (BPH) and prosta-
titis, as well as manipulation and medical interventions
of the prostate lead to serum PSA elevations and subse-
quently limit the specificity of PSA for cancer detection* Correspondence: katarina@manu.edu.mk
1Research Centre for Genetic Engineering and Biotechnology “Georgi D Efremov”,
Macedonian Academy of Sciences and Arts, Krste Misirkov 2, 1000 Skopje,
Republic of Macedonia
Full list of author information is available at the end of the article
© 2015 Davalieva et al.; licensee BIoMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[4]. Additionally, 15% of PCa cases occur in men with
normal serum PSA levels [5]. These data have encouraged
considerable investigation into the search for novel
PCa biomarkers.
The rise of –omics technologies in recent years and
their use in PCa research has delivered a number of new
potential biomarkers for PCa [6-8]. These included pro-
teins, fusing genes, RNA transcripts and epigenetic modi-
fications of DNA. Among the available technologies,
proteomics has shown large potential in identification of
PCa biomarkers [9,10]. As a result of the found differences
in protein expression profiles between BPH and PCa, and
among different types and grades of cancer, a number of
proteins in tissue and biological fluids (serum, plasma,
urine, seminal plasma) were identified as potential diag-
nostic or prognostic markers for PCa. Prostate tissue, al-
though a rich source of potential PCa biomarkers, has theral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cant morbid risk [11]. On the other hand, a screening pro-
cedure based on biological fluid testing is highly desirable
because of the minimally invasive and low-cost procedures
for collecting samples. Hence, the current extensive inves-
tigation in PCa biomarkers is mostly oriented to the identi-
fication of highly specific non-invasive and easily accessible
biomarkers in urine, seminal plasma and minimally inva-
sive blood samples.
The number of newly identified diagnostic PCa bio-
marker candidates in biological fluids is rising over the
time. Those found in serum include various precursor
forms of PSA [12,13], α-2-macroglobulin [14,15], Zinc-α2-
glycoprotein [14,16,17], Pigment epithelium-derived factor
[16,18], Eukaryotic translation elongation factor 1 alpha 1,
Fibronectin 1 [14], Chemokine ligand 16, Pentraxin 3,
Spondin 2, Follistatine [19,20], panels of serum proteins
[21] and many other soluble factors and intracellular
proteins involved in structural or metabolic functions. Can-
didates for urine biomarkers include Annexin A3 [22],
Inter-alpha-trypsin inhibitor heavy chain 4 [23], CD90 [24],
Calgranulin/MRP-14 [25], Semenogelin 1, Uromodulin [26]
and Engrailed-2 [27]. Some of these proteins have been
identified in independent studies with different proteomics
methods and their usefulness is yet to be validated in a
large cohort within and across different ethnic populations.
However, most of the data obtained until now is quite het-
erogeneous and there is a small percentage of overlap be-
tween independent studies. No single test or proposed
biomarker to date can fulfill the requirements for the ideal
PCa diagnostic biomarker and the next PCa screening tool.
Furthermore, it is becoming clearer that the ideal PCa diag-
nostics test will most likely be based not on a single but
multiple biomarkers, due to the clinical heterogeneity of
the cancer and the need to distinguish the disease from
greatly prevalent inflammatory and benign conditions [6,8].
This highlights the necessity of future extensive compara-
tive analysis of well-defined samples for identification of a
reliable diagnostic PCa biomarker or biomarker panel.
The aims of this study were to characterize the pattern
of differential protein abundances in urine of PCa and
BPH patients using two-dimensional difference in gel poly-
acrylamide gel electrophoresis (2-D DIGE) coupled with
mass spectrometry (MS) and to identify a biomarker or
marker panel for non-invasive PCa diagnosis preferentially
with greater specificity and sensitivity from the ones that
are currently in use. Another objective was to compare
our results with those of other published studies and to as-
sess the level of compatibility across different technological
platforms used and different ethnic background of sam-
ples. The identified proteins with differential abundances
between the PCa and BPH groups from this study were
significantly associated with the Acute Phase Response
Signaling pathway. We have been able to successfullyvalidate these findings by confirming the differential abun-
dance of TF, HP and AMBP in urine in an independent
validation set. The results from this study may provide a




The number of the detected spots in the DeCyder DIA
workspaces in all gels ranged from 1308 to 1577. In the
BVA module, the spots were matched among 4 gels with
an average of 1063 matched spots. One hundred and thirty
four spots showed statistically significant (p < 0.05) 1.8 fold
variation or more in abundance. However, upon manual
checking of the spot quality, the majority of the protein
spots with differential abundance were either part of the
most abundant protein in the urine, later identified as
albumin [28], or were low quality spots. Therefore, only
41 spots were selected for further analysis (Figure 1). All
of these spots fulfilled the criteria for presence in all spot
maps. Among these, 22 spots showed higher abundance in
the PCa group (up-regulated) and 19 spots had lower
abundance in PCa (down-regulated).
Principle component analysis and hierarchical clustering
analysis of the 41 spots with differential abundance were
performed by EDA module, available within the DeCyder
software (Figure 2). Two-dimensional scatter plots of the
principal components of urine samples showed a good
clear separation between samples from PCa and BPH
patients (Figure 2A). Hierarchical clustering analysis
(Figure 2B) showed that, based on the abundance pattern
of the 41 spots, samples from PCa and BPH groups form
two distinct separate clusters.
Identification and interpretation of proteins with
differential abundance
All of the 41 spots with differential abundance were
identified by MALDI-MS. Fold changes of the 41 identi-
fied protein spots in the two groups along with the
detailed Mascot search results are given in Table 1.
Several proteins were identified in multiple spots, most
likely due to posttranslational modification leading to
shifts in the 2-D. So, the identified spots with differential
abundance equaled to 23 distinct proteins, among which
14 were up-regulated and 9 were down-regulated in PCa.
The 23 identified proteins were grouped into different
classes based on sub cellular and functional information
available (Additional file 1: Figure S1). The majority of the
proteins were enzymes (30%), transporters (22%), enzyme
inhibitors (13%) and proteins of unknown function (17%).
Most of the proteins were secreted (74%), 17% were
cytoplasmic and only 8% membrane or nucleus proteins.
Binding was the major molecular function (50%), followed
by catalytic activity (27%) and transport (15%). The GO
Figure 1 Representative 2-D map of the urine proteome obtained by using IEF on pH 4–7 IPG strip and 2-D gel electrophoresis on
12.5% SDS-PAGE. All proteins with differential abundance between studied groups are marked with numbered arrows. Details of these proteins
identified by MALDI MS are tabulated in Table 1. Proteins with increased abundance in PCa are marked with red arrows.
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processes in which the identified proteins are putatively
involved. Detailed information regarding biological func-
tion is given in Table 2.
The IPA analysis of associations between our set of pro-
teins and known biological pathways showed significant as-
sociation with the Acute Phase Response Signaling pathway
(p = 6,99E-14). Nine of the 23 proteins with differential
abundance are included in this pathway: α-1-microglobulin/
bikunin (AMBP), apolipoprotein A-I (APOA1), fibrinogen
alpha chain (FGA), fibrinogen gamma chain (FGG), hapto-
globin (HP), inter-alpha-trypsin inhibitor (ITIH4), alpha-1-
antitrypsin (SERPINA1), transferrin (TF) and transthyretin
(TTR) (Figure 3A).
According to the IPA functional classification - Dis-
eases and Disorders, 9 of our proteins (APOA1, CD59,
FGG, GSN, HSPG2, MASP2, PTGDS, SERPINA1 and
TYMP) are significantly associated with the category -
Organism Injury and Abnormalities, sub category –
Lesion formation (p = 9,05E-10) while in Molecular
and Cellular Function category, 14 proteins (APOA1,
CD59, FGA, GSN, HP, HSPG2, ILF2, ITIH4, PTGDS,SERPINA1, TF, TTR, UMOD and TYMP) were found
significantly associated with cell death (p = 2,29E-5).
The highest ranked protein network of functional associ-
ations between the differentially expressed proteins accord-
ing to IPA was Cancer, Organism Injury and Abnormalities
and Gastrointestinal Disease (score 46) (Figure 3B). Seven-
teen out of 23 proteins with differential abundance (TTR,
HSPG2, CD59, FGA, FGG, GC, HP, APOA1, TF, ITIH4,
AMBP, UMOD, SERPINA1, GSN, TYMP, PTGDS and
LMAN2) are closely connected in the network through
three major nodes: P38 Mitogen-activated protein kinase
(P38 MARK), extracellular-signal-regulated kinase 1/2
(ERK1/2) and pro-inflamatory cytokines.
Our set of proteins was further analyzed using IPA bio-
marker filter which allows matching the input protein list
with known disease profiles consisting of maps, networks
and lists of biomarkers known for a disease. Results re-
vealed that 12 of the proteins (AMBP, APOA1, FGA,
GSN, HP, HSPG2, MASP2, PTGDS, SERPINA1, TF, TTR
and TYMP) are predicted markers for prostate cancer
(Figure 3C). The majority of these proteins (7/12) are also
part of the Acute Phase Response Signaling pathway.
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Figure 2 Principal component analysis and hierarchical cluster analysis of the proteins with differential abundance. (A) Scatter plots of
the principal component analysis where green dots represent urine samples from BPH patients and red dots samples from PCa patients. (B) The
hierarchical clustering result: higher abundance in PCa group is coloured in red, the lower ones in green. Column descriptors indicate the
4 samples per group (B = BPH; C = PCa) and the labeling dye, while the row descriptors indicate proteins with their spot numbers (given in
Table 1). The dendrograms represent the distances between the clusters.
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Five proteins (TF, SERPINA1, APOA1, AMBP and HP)
were further evaluated by immunoturbidimetry to test
whether quantitative measurement in urine could be uti-
lized as a diagnostic tool to distinguish patients with PCa
and BPH. We manage to determine quantitatively the
urine levels of three proteins (TF, AMPB and HP), while
the concentrations of SERPINA1 and APOA1 were below
the assays LOD. The measured concentrations of TF,
AMPB and HP were normalized to urine creatinine tomake correction for variations in urinary concentration.
The results confirmed the abundance levels obtained by
the DIGE experiment (Figure 4A). The concentration of
AMPB in the PCa group showed a significantly higher
level that in BPH group (Mann–Whitney U-test, p = 0.04).
The levels of TF and HP were significantly higher in the
BPH compared to the PCa group yielding p = 0.015 and
p = 0.031, respectively (Figure 4B). Receiver operating
curve (ROC) determined the diagnostic accuracy of the
proteins in the validation set, using the histopathological

















1 0.010 −2.53 Serotransferrin TRFE_HUMAN 79.29 6.81 98 80 3.1E-06 10/15 21
2 0.010 −2.64 Serotransferrin TRFE_HUMAN 79.29 6.81 200 47 2.0E-16 23/43 38
3 0.010 −2.64 Serotransferrin TRFE_HUMAN 79.29 6.81 243 57 1.0E-20 22/30 40
4 0.033 −2.17 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 81 56 1.9E-04 12/31 31
5 0.002 −5.21 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 128 82 3.2E-09 18/34 36
6 0.002 −4.34 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 194 51 8.1E-16 23/43 53
7 0.002 −3.66 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 74 109 7.7E-04 12/28 27
8 0.001 −3.05 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 178 63 3.2E-14 20/31 41
9 0.000 −4.27 Alpha-1-antitrypsin A1AT_HUMAN 46.89 5.37 66 102 4.9E-03 9/17 26
10 0.010 −3.18 Vitamin D-binding protein VTDB_HUMAN 54.52 5.40 135 65 6.4E-10 12/24 50
11 0.011 −6.11 Fibrinogen gamma chain FIBG_HUMAN 52.10 5.37 164 108 8.1E-13 17/30 47
12 0.019 −4.41 Thymidine phosphorylase TYPH_HUMAN 50.32 5.36 64 104 7.4E-03 5/13 25
13 0.036 2.59 Gelsolin GELS_HUMAN 86.04
(52.48)
5.90 (5.34) 80 81 2.0E-03 9/15 16
14 0.004 4.75 Fibrinogen alpha chain (fragment) FIBA_HUMAN 95.65 (~50) 5.70 (4.65) 91 99 1.6E-05 10/18 15
15 0.003 2.47 Endonuclease domain-containing 1 protein ENDD1_HUMAN 55.72 5.55 104 122 8.1E-07 9/13 20
16 0.000 3.07 E3 ubiquitin-protein ligase rififylin RFFL_HUMAN 41.74 5.33 59 97 2.7E-02 5/12 26
17 0.009 2.72 Inter-alpha-trypsin inhibitor heavy chain H4
(fragment)
ITIH4_HUMAN 103,52 (~45) 6,51 (5,00) 64 51 9.1E-03 13/26 12
18 0.004 2.66 Inter-alpha-trypsin inhibitor heavy chain H4
(fragment)
ITIH4_HUMAN 103.52 (~45) 6.51 (5.15) 88 134 2.9E-05 11/26 13
19 0.001 4.75 Quinone oxidoreductase-like protein 1 QORL1_HUMAN 39.07 5.49 66 91 4.9E-02 4/12 12
20 0.005 3.17 Interleukin enhancer-binding factor 2 ILF2_HUMAN 43.26 5.19 62 82 3.0E-02 5/13 19
21 0.002 5.07 Vesicular integral-membrane protein VIP36 LMAN2_HUMAN 40.54 6.46 80 75 1.9E-04 7/14 21
22 0.041 2.26 Protein AMBP AMBP_HUMAN 39.87 5.95 86 15 5.5E-05 8/15 22
23 0.048 2.25 Protein AMBP AMBP_HUMAN 39.87 5.95 93 78 9.9E-06 10/24 23
24 0.044 2.26 Protein AMBP AMBP_HUMAN 39.87 5.95 94 109 8.4E-06 10/19 24
25 0.035 2.35 Protein AMBP AMBP_HUMAN 39.87 5.95 130 93 2.0E-09 15/35 37
26 0.023 3.33 Prostaglandin-H2 D-isomerase PTGDS_HUMAN 21.24 7.66 61 52 1.8E-02 7/17 32
27 0.033 3.43 Prostaglandin-H2 D-isomerase PTGDS_HUMAN 21.24 7.66 64 23 7.7E-03 8/36 33
28 0.005 −3.25 Apolipoprotein A-I APOA1_HUMAN 30.75 5.56 116 57 5.1E-08 16/53 46












Table 1 List of proteins with differential abundance identified by MALDI-MS (Continued)
30 0.009 3.55 Basement membrane specific heparan sulphate




6.06 (5.47) 204 62 1.1E-15 15/33 88
31 0.001 4.60 CD59 glycoprotein CD59_HUMAN 14.79 6.02 58 103 2.9E-02 4/7 21
32 0.006 3.11 CD59 glycoprotein CD59_HUMAN 14.79 6.02 58 32 2.9E-02 4/7 21
33 0.000 4.17 CD59 glycoprotein CD59_HUMAN 14.79 6.02 61 47 1.6E-02 5/15 28
34 0.001 6.56 Secreted and transmembrane protein 1 SCTM1_HUMAN 27.30 7.00 66 34 4.9E-03 6/13 22
35 0.019 −5.51 Haptoglobin (fragment, alpha 2 chain) HPT_HUMAN 45.86 (~16) 6.13 (6.20) 73 79 9.3E-03 4/11 28
36 0.017 2.26 Mannan-binding lectin serine protease 2
(chainA, Human MBL associated protein 19)
MASP2_HUMAN 77.19
(19.53)
5.39 (5.44) 127 24 5.5E-08 7/14 (8/14) 37
37 0.015 −5.86 Haptoglobin (fragment, alpha 2 chain) HPT_HUMAN 45.86 (~16) 6.13 (6.20) 88 32 7.5E-04 7/18 34
38 0.024 −6.58 Haptoglobin (fragment, alpha 2 chain) HPT_HUMAN 45.86 (~16) 6.13 (6.20) 80 41 1.9E-04 11/34 31
39 0.004 6.21 Secreted and transmembrane protein 1 SCTM1_HUMAN 27.30 7.00 75 47 6.1E-04 6/9 22
40 0.012 −3.39 Transthyretin TTHY_HUMAN 15.99 5.52 160 32 2.0E-12 10/27 73












Table 2 Functional characterization of the proteins with differential abundance between PCa and BPH and association with urogenital cancers
Protein name Symbol Expression
(PCa/BPH)
Biological function Association with PCaa Association with urogenital cancersa
Serotransferrin TF Down-regulated Iron transport, acute-phase response,
stimulation of cell proliferation
Down-regulated, serum [21];
Down-regulated, urine [29]
Alpha-1-antitrypsin SERPINA1 Down-regulated Blood coagulation, acute phase
response, hemostasis
Differentially expressed, tissue [30];
Up-regulated, serum [31]; Down-
regulated, serum [21]
Up-regulated, urine, bladder cancer [32];
Vitamin D-binding protein GC Down-regulated Vitamin D metabolic process, vitamin
transport, transmembrane transport
Differentially expressed, tissue [33]
Fibrinogen gamma chain FGG Down-regulated Cell activation, protein complex
assembly, response to stress, signal
transduction, blood coagulation,
hemostasis
Differentially expressed, tissue [30] Degradation products in urine - markers
for bladder cancer [34]; Up-regulated,
urine, bladder cancer [35]
Thymidine phosphorylase TYMP Down-regulated DNA replication, angiogenesis,
response to stimulus
Potential marker for PCa [28] Up-regulated, tissue, renal cell carcinoma
[36]
Gelsolin GSN Up-regulated Promote the assembly of monomers
into filaments, transport, apoptosis,
response to stress
Differentially expressed, tissue [33];
Down-regulated, tissue [37]
Fibrinogen alpha chain FGA Up-regulated Cell activation, protein complex
assembly, response to stress, signal
transduction, blood coagulation,
hemostais
Degradation products in urine - markers
for bladder cancer [34]; Up-regulated,
urine, bladder cancer [35]
Endonuclease domain-containing 1 protein ENDOD1 Up-regulated Unknown, may act as DNase/RNase Potential marker for PCa [28]
E3 ubiquitin-protein ligase rififylin RFFL Up-regulated Protein transport, proteolysis,
apoptosis
Potential marker for PCa [28]






Quinone oxidoreductase-like protein 1 CRYZL1 Up-regulated Quinone cofactor metabolic process,
cellular metabolic process
Potential marker for PCa [28]
Interleukin enhancer-binding factor 2 ILF2 Up-regulated Immune response, regulation of
transcription, nucleobase-containing
compound metabolic process
Potential marker for PCa [28]




AMBP Up-regulated Cell adhesion, immune response,
regulator of biological processes,


















Table 2 Functional characterization of the proteins with differential abundance between PCa and BPH and association with urogenital cancers (Continued)
Apolipoprotein A-I APOA1 Down-regulated Regulation of cytokine production,
regulation of lipid transport, lipid
metabolism
Differentially expressed, tissue [30];
Down-regulated, serum [31];
Down-regulated, serum [21]
Up-regulated, urine, bladder cancer [35]
Laminin G Like Domain 3 From Human
Perlecan
HSPG2 Up-regulated Developmental processes, cell
adhesion, cell differentiation,
localization
CD59 glycoprotein CD59 Up-regulated Response to stress, cell surface
receptor linked signal transduction,
blood coagulation, hemostasis,
response to external stimulus
Secreted and transmembrane protein 1 SECTM1 Up-regulated Immune response, regulation of
signal transduction, multicellular
organismal development
Haptoglobin (α-chain) HP Down-regulated Proteolysis, cellular iron ion
homeostasis, response to stress,
defense response, metabolic process
Down-regulated, urine [38]; Up-regulated, urine, bladder cancer [35]
Down-regulated, tissue [39];
Down-regulated, serum [21]
Mannan-binding lectin serine protease 2 MASP2 Up-regulated Complement activation, lectin
pathway, activation of immune
response
Transthyretin TTR Down-regulated Transport, localization, establishment
of localization
Up-regulated, serum [31]
Uromodulin UMOD Down-regulated Response to stress, cellular defense
response, regulation of cell
proliferation
Down-regulated, urine [26]












Figure 3 Pathways and networks associated with proteins with differential abundance according to IPA. (A) The top canonical pathway
significantly associated with the differentially expressed proteins - Acute Phase Response Signaling (p = 6,99 e−14). (B) Highest ranked protein network
of functional associations between 23 proteins with differential abundance - Cancer, Organism injury and abnormalities and Gastrointestinal Disease.
Most of the proteins with differential abundance are closely connected in the network through three major nodes: P38 MARK, Pro-inflamatory cytokine
and ERK1/2. The network is graphically displayed with proteins as nodes and the biological relationships between the nodes as lines. The color of the
shapes indicates the degree of over-expression (red) or under-expression (green) of the corresponding protein in PCa compared to BPH samples. Direct
connection between molecules is represented by a solid line and indirect connection by broken line. The length of a line reflects published evidence
supporting the node-to-node relationship concerned. (C) Selected subset of proteins with differential abundance associated with cancer in humans or
cancer cell lines.
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sification (Figure 4C). The area under the curve (AUC) for
TF was 0.754 (p = 0.002, 95% CI 0.596-0.912), for AMBP
was 0.738 (p = 0.005, 95% CI 0.574-0.903) and for HP was0.723 (p = 0.008, 95% CI 0.558-0.888). The optimal cutoffs
for the proteins were: 12.81 mg TF/g creatinine (93.8%
specificity, 56.3% sensitivity); 6.51 mg AMBP/g creatinine
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AUC=0.820
Figure 4 Validation of candidate biomarkers for the diagnosis of PCa. (A) 2-DE profiles of TF, AMBP and HP abundance in independent
urine samples from BPH and PCa patients obtained by 2-D DIGE. Proteins with differential abundance were represented by clusters of 3–4 spots,
highlighted with oval lines. Four gels corresponding to samples from each group were shown. (B) TF, AMBP and HP levels in urine of PCa and
BPH patients, expressed as relative ratio to urine creatinine and obtained by immunoturbidimetry. AMBP level in PCa was significantly higher than
that in BPH while TF and HP levels in PCa were significantly lower than in BPH (Mann–Whitney U-test, P < 0.05). In the combined dot/box plot
graphs, concentration data (blue diamond), median (−), 25th and 75th percentiles and mean (+) are shown. (C) Urinary TF, AMBP and HP distinguish
PCa on independent series of urine samples from patients with PCa and BPH. The optimal cutoffs for the proteins were: 12.81 mg TF/g creatinine
(93.8% specificity, 56.3% sensitivity); 6.51 mg AMBP/g creatinine (50.0% specificity, 93.8% sensitivity); 2.40 mg HP/g creatinine (56.3% specificity, 93.8%
sensitivity). ROC curves were based on series of 32 urine samples. (D) The diagnostic accuracy of TF, AMBP and HP combinations using logistic
regression model. The combination AMBP and HP yielded highest diagnostic accuracy (AUC = 0.848).
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Davalieva et al. Proteome Science  (2015) 13:2 Page 11 of 17creatinine (56.3% specificity, 93.8% sensitivity). The values
of AUC and diagnostics cutoff for serum PSA in the valid-
ation set were 0.754 (p = 0.001, 95% CI 0.600-0.907) and
5.50 ng/ml (50.0% specificity, 93.8% sensitivity), respect-
ively (data not shown).
Using a logistic regression model, the diagnostic accur-
acy of various combinations of TF, AMBP, HP and PSA
were tested (Table 3 and Additional file 2). The combin-
ation of TF, AMBP and HP increased the individual
diagnostic accuracy (Figure 4D). The highest AUC was
obtained for the combination of HP and AMBP (AUC =
0.848). Inclusion of PSA or TF into the HP/AMBP test
has not yielded an improved accuracy. The combination
of each of the tested proteins with PSA also resulted in
increased AUC, except for the AMBP where addition of
PSA did not improve the diagnostic accuracy (0.773
(AMBP + PSA) vs. 0.738 (AMBP) vs 0.754 (PSA).
Discussion
The low sensitivity and specificity of current diagnostic
methods for prostate cancer highlights the need for im-
provement in this area. In this study, we focused on
identification of non-invasive biomarkers for PCa using
urine samples from two age-matched groups of patients
with histologically characterized diagnosis of PCa and
BPH, respectively.
Urine is an attractive material in clinical proteomics
because it can be sampled non-invasively in large quan-
tities, contains generally soluble proteins which does not
undergo significant proteolytic degradation and has lower
dynamics range of protein concentrations compared to
other biofluids [40]. Urine proteome represents modified
ultrafiltrate of plasma combined with proteins derived
from kidney and urinary tract [41]. Proteomic analysis of
urine has suggested that it contains disease-specific infor-
mation for a number of kidney diseases, cancers related to
the urogenital system such as kidney, bladder and prostate
cancer, as well as various non-nephrological/urogenital
diseases [42]. The comparative proteomics studies for PCa
biomarker identification in urine have reported a number
of proteins with differential abundance between PCa and
BPH, with some of them proposed as potential biomarkers
for PCa diagnosis [22-27,43,44]. However, most of theseTable 3 The diagnostic accuracy of various combinations
of TF, AMBP, HP and PSA expressed as area under the
ROC curve (AUC) using logistic regression model
Protein combinations tested
TF √ √ √ √ √
HP √ √ √ √ √ √
AMBP √ √ √ √ √ √
PSA √ √ √ √ √
AUC 0.840 0.848 0.848 0.848 0.832 0.820 0.840 0.836 0.773candidate biomarkers still lack an extensive validation and
haven’t been introduced into clinical practice. The high
variability of the reported data so far highlights the need
for more research in this area with consistent sample col-
lection, storage methods and sample processing. The sam-
ples used in this study were collected and stored according
to the standard protocol for urine collection with no
addition of protease and phosphatase inhibitors and no
pH adjustment [45]. Sample processing and manipulation
were minimal without depletion of the highly abundant
proteins, to exclude the possibility of losing low abundant
proteins or low molecular weight proteins that exist in
complexes with the highly abundant proteins. In addition,
we have used the 2-D DIGE/MS platform who although
has lover dynamic range of protein quantification than
LC-MS based platforms is still an indispensable platform
in proteomics, particularly for the visualization of the
proteome and assessment of the individual posttransla-
tional modifications [46].
Our proteomic data revealed 23 proteins with differen-
tial abundance in urine of PCa patients compared to
BPH patients. In order to analyze the impact of co-
regulation of protein expression in context of biomarker
identification, principal component analysis and hier-
archical clustering has been applied on the differential
protein expression data. Here, we have detected a clear
separation of the two distinct groups (PCa and BPH)
based on the abundance pattern of the 23 proteins. The
clustering of samples showed formation of two separate
clusters, clearly separating benign from tumor samples
with general observation that PCa/BPH classification
cannot be based on one individual protein, but on ex-
pression pattern of the selected subset of proteins.
Gene Ontology (GO) search for biological processes
classified these proteins into proteins involved in the im-
mune response and response to stimuli, regulators of
different biological processes (transcription, prolifera-
tion, signal transduction, cytokine production), transport
proteins involved in transport of ions, proteins and lipids
and proteins involved into different metabolic processes.
Many of the proteins with differential abundance in
this study have been associated with PCa or cancers of
the urogenital system (Table 2). Overall, 17 of the identi-
fied proteins have been associated specifically with PCa
in different proteomics studies. Our initial study of the
protein components from urine of PCa patients, pointed
out 11 proteins that might have some role in the patho-
genesis of prostate cancer by comparison with other
published studies analyzing normal urine proteome [28].
Five of these proteins (TYMP, ENDOD1, RFFL, CRYZL1
and ILF2) were detected with differential abundance
when comparing to BPH group. In comparative studies
using urine, the abundance levels of TF, ITIH4, AMPB,
PTGDS, HP and UMOD were the same as in our study
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also studies where opposite abundance levels were re-
ported as well [31,38]. The abundance level of APOA1
in our study was the same as in a study using serum
while the levels of SERPINA1 and TTR were found op-
posite to ours [31]. Some of the proteins such as SER-
PINA1, FGG, FGA, APOA1 and HP were also found
with differential abundance in urine in proteomics stud-
ies of bladder cancer, and TYMP in tissue in renal cell
carcinoma, but mostly with opposite abundance level
compared to our study [32,34-36].
IPA analysis of our set of proteins revealed significant
association with the Acute Phase Response Signaling path-
way. Nine of our proteins (AMBP, APOA1, FGA, FGG,
HP, ITIH4, SERPINA1, TF and TTR) were acute phase re-
sponse proteins. The acute phase response is a rapid in-
flammatory response that provides protection against
microorganisms using non-specific defense mechanisms
[47]. The association of our proteins with this pathway
complies with the generally accepted observation that
inflammation is often observed in tumors and appears
to play a dominant role in the pathogenesis of various can-
cer types [48]. Moreover, the highest ranked protein net-
work of functional associations between the differentially
expressed proteins revealed close connected in the net-
work through three major nodes: P38 Mitogen activated
protein kinase (P38 MARK), extracellular-signal-regulated
kinase 1/2 (ERK1/2) and pro-inflamatory cytokines. P38
MARK and ERK1/2 are members of the mitogen activated
protein kinase super family that can mediate cell prolife-
ration and apoptosis [49]. Abnormal regulation of the
MAPK pathways have been reported for a wide range of
diseases including many cancers [50]. The pro-inflamatory
cytokines interleukin-6 (IL-6), tumor necrosis factor alpha
(TNFα) and interleukin-1 beta (IL-1β) are critical media-
tors of the systemic inflammatory response and main
stimulators for the synthesis of an acute-phase response
proteins [48]. These cytokines have been implicated in a
variety of diseases including cancer where their role is
more likely to contribute to tumour growth, progression
and immunosuppression than to an effective host-antitumor
response [51]. For this reason, cancer patients frequently
present changes in various systemic parameters, compris-
ing alterations in the level of serum inflammatory cyto-
kines, acute-phase proteins and total albumin [52]. And
finally, IPA biomarker filter revealed 12 proteins as candi-
date biomarkers for prostate cancer with majority being
acute phase proteins.
A number of well characterized acute phase proteins
have been linked to distinct cancer types and stages of ma-
lignancy [53]. The field of acute phase proteins as cancer
biomarkers has vast potential. The identification of spe-
cific proteomic expression patterns in acute phase proteins
related to cancer offers promise for novel diagnosticmarkers. Having in mind this and results from the IPA
analysis, we considered the possibility of using acute phase
response proteins found in urine as non-invasive bio-
markers for PCa. This was additionally encouraged from
the fact that the abundance pattern of 4 acute phase
response proteins in our study differed from the defined
expression (Figure 4A). Protein AMBP shows decreased
plasma concentration during the acute phase response, but
in our study increased expression in PCa was observed.
Proteins HP, SERPINA1 and FGG showed decreased ex-
pression in PCa, opposite to the plasma concentration dur-
ing the acute phase response. On the other hand, the
expression levels of the acute phase response proteins in
this study correlated with the observed levels in a number
of independent studies on PCa, with minor exceptions
where opposite abundance levels were also reported
(reviewed in Table 2).
From the total set of acute phase response proteins de-
tected with differential abundance, we highlighted TF,
AMBP, HP, APOA1 and SERPINA1. These proteins were
detected as clusters of 2-6 spots with the same abun-
dance levels within clusters and therefore exhibited
higher potential to be associated with PCa than proteins
identified in only one spot. Notably, AMBP, HP and
SERPINA1 were particularly interesting for us since they
demonstrated the same abundance levels as in other
proteomics studies and opposite abundances from the
acute phase response. So, we chose to further evaluate
the diagnostic potential of these 5 proteins in an inde-
pendent set of patients by quantitative measurement in
urine. Using immunoturbidimetry, we manage to deter-
mine quantitatively the urine levels of TF, AMBP and
HP in all samples from the validation set. The results
showed that there was a significant difference (p<0.05)
in the urine levels of these proteins between PCa and
BPH group, confirming the expression levels obtained by
the DIGE experiment. The observed diagnostics accur-
acy of the proteins was moderate, with the lowest being
found for HP (0.723 at 2.40 mg/g creatinine) and the
highest for TF (0.754 at 12.81 mg/g creatinine). Similar
diagnostics accuracy was found for serum PSA (0.754).
A number of logistic regression models using combina-
tions of TF, AMPB, HP and PSA were also tested in
order to estimate if the diagnostic accuracy improves
with the combination of proteins. In general, combin-
ation of proteins showed increased AUC with the high-
est value obtained for HP/AMBP. So, although the
observed accuracy of the individual proteins were similar
to the PSA, the combination of HP and AMBP yielded
greater accuracy compared to individual tests. The results
indicated that HP/AMBP combination could be potential
biomarker set for the diagnosis of PCa with improved
accuracy compared to the PSA. In addition, the pro-
posed biomarker set complies with the requirements for
Davalieva et al. Proteome Science  (2015) 13:2 Page 13 of 17diagnostics biomarker as it is easily accessible, non-invasive,
quickly quantifiable and economical. Though maybe these
proteins are not specific proteins for PCa, they could be-
come an important check index and improve the sensitivity
and specificity for early diagnosis.
Conclusions
Our study indicated that the 2-D DIGE/MS proteomic
analysis of urinary proteins is feasible for the identification
of non-invasive biomarkers for PCa diagnosis. As a result
of this approach, a set of acute phase response proteins
found in urine could serve as a diagnostics biomarkers for
PCa. Moreover, our results confirmed the importance of
previously identified proteins and highlighted new pro-
teins that can add information regarding the pathophysio-
logical mechanisms of PCa. However, further studies are
needed to validate the proposed biomarkers in independ-
ent cohorts and to evaluate the diagnostic potential of the
rest of the differentially expressed proteins found in this
study which might further improve the diagnostics accur-
acy of the proposed set.
Methods
Samples
We analyzed 56 urine samples from patients with clinically
and histological confirmed PCa and BPH obtained from
the University Clinic for Urology, University Clinical Centre
“Mother Theresa”, Skopje, Republic of Macedonia. In-
formed consent for the use of these samples for research
purposes was obtained from the patients in accordance
with the Declaration of Helsinki. The study has been
approved by the Ethics Committee of the Macedonian
Academy of Sciences and Arts.
The patients referred to hospital because of clinical
symptoms. The diagnosis was based on histological evalu-
ation of tissues obtained by transurethral resection of the
prostate (TURP) for BPH and whole prostate gland ob-
tained by radical prostatectomy for PCa patients. None of
the patients received preoperative therapy. Patient’s clin-
ical records including histology grading, tumor stage and
pre-operative PSA were reviewed to preselect the urine
samples used in this study (Additional file 3: Table S1).
BPH patients were preselected to be without signs of in-
flammation (prostatitis). Urine samples for the 2D-DIGE
analysis (screening set) consisted of 8 samples from PCa
and 16 samples from BPH patients. Validation of the se-
lected candidate biomarkers was done on an additional 16
PCa and 16 BPH urine samples. In the screening cohort,
the mean values (± SD) for PSA, Gleason score and age
were as follows: serum PSA was 9.0 ± 3.9 (ng/ml) for the
PCa group and 6.4 ± 3.2 (ng/ml) for the BPH group; age
was 69.0 ± 6.6 years for PCa and 65.3 ± 7.3 years for BPH;
Gleason score was 7.4 ± 1.1. In the validation cohort, the
mean values (± SD) for PSA, Gleason score and age wereas follows: serum PSA was 8.7 ± 3.2 (ng/ml) for PCa group
and 5.6 ± 2.9 (ng/ml) for BPH group; age was 67.4 ±
5.0 years for PCa and 69.2 ± 8.2 years for BPH; Gleason
score was 7.4 ± 1.1.
The first morning urine (3–10) ml was collected from
the patients prior to clinical intervention and stored on
ice for short period (<1 h). Samples were centrifuged at
1000 g, for 10 min to remove cell debris and casts, ali-
quoted in 1.5 ml tubes and stored at −80°C until use.
The stored urine samples were thawed and for each
sample, proteins were isolated in triplicate from 100 μl
urine using 2-D Clean-UP Kit (GE Healthcare) accord-
ing to the manufacturer’s instructions. The pellets from
each replicate were dissolved in 10 μl of UTC buffer
(8 M Urea, 2 M Thiourea, 4% CHAPS), pooled together
for each sample, quantified by the Bradford method [54]
in duplicate against a standard curve of Bovine Serum
Albumin (BSA) and stored at −80°C until use.
2-D DIGE, imaging and analysis
Equal amounts of protein extract from urine were pooled
for the DIGE labeling: 2 PCA samples and 4 BPH samples
per labeling reaction respectively. The pH of protein sam-
ples was adjusted to 8.5 with 1.5 M Tris–HCl. Proteins
were labeled with the CyDye DIGE Fluor minimal dyes
(GE Healthcare) following manufacturer’s instructions.
Forty five micrograms of protein per pool were minimally
labeled with 400 pmol of Cy3 or Cy5, respectively. Cy2
was used to label an equivalent amount of internal stand-
ard containing equal amounts of all samples. Reactions
were stopped with 10 mM L-lysine for 10 min. The
samples were randomized between gels to ensure an even
distribution between those labelled with Cy3 and Cy5
minimal dyes and to avoid repetitive linking of the same
sample type with the same dye on multiple gels.
The first dimension of the 2-D DIGE analysis was
performed using 24 cm Immobiline Drystrip gels (GE
Healthcare) with linear pH 4–7 gradient. The separate
CyDyes labeling reactions were combined, rehydration
buffer (8 M Urea, 2 M Thiourea, 2% (w/v) CHAPS,
10 mM DTT, 1.2% (v/v) IPG-Buffer pH4-7, Trace of
Bromophenol Blue) was added to a final volume of 450 μl
and the gels were passively rehydratated overnight in IPG-
Phor cassettes. Isoelectric focusing (IEF) was performed
on the Ettan IPGphor 3 system (GE Helthcare) under the
following conditions: 3 h at 300 V, 7 h gradient to 1000 V,
3 h gradient to 10000 V and 4 h 15 min at 10000 V, until
total a of 64.5 kVh was reached. The focused proteins in
the IPG strips were immediately equilibrated in two incu-
bation steps, each lasting 15 min, at room temperature. In
the first step, the equilibration buffer (6 M Urea, 2% SDS,
30% Glycerol, 50 mM Tris–HCl, pH 8.6) was supple-
mented with 1% (w/v) DTT for reduction, followed by
alkylation in the same buffer containing 4.7% (w/v)
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was carried out onto 12.5% homogeneous polyacrylamide
gels using the Ettan DALTsix system (GE Healthcare), at
2.5 W per gel for 30 min, followed by 16 W/gel for 5 h.
The four 2-D DIGE gels were scanned on an Ettan
DIGE imager (GE Healthcare). Gel images were normal-
ized by adjusting the exposure time to obtain appropriate
pixel value without any saturation. All gels were scanned
at 100 dpi resolution. Images were cropped using Image
QuantTL software v7.0 (GE Healthcare) to remove areas
extraneous to the gel image.
DIGE images were analyzed using DeCyder 2-D Differ-
ential Analysis Software v7.1 (GE Healthcare). Spot detec-
tion and normalization was processed by the Differential
Analysis (DIA) module using the estimated number of
spots set to 3000 and spot volume < 30000 as exclusion
filter. Gel-to-gel comparison and statistical analysis of the
degree of difference in standardized protein abundance
between PCa and BPH groups were performed with the
Biological Variation Analysis (BVA) module. Matching
was further improved by using landmarks and manually
confirming potential spots of interest. Proteins with statis-
tically significant differential abundance were selected
based on two criteria: t-test < 0.05 and ratio > 1.8. Each
spot was manually verified for an acceptable three dimen-
sional characteristic protein profile and for adequate ma-
terial for subsequent mass spectrometry identification.
Spots not meeting these criteria were excluded from fur-
ther analysis. The Extended Data Analysis (EDA) module
of DeCyder and was used for principal component analysis
and clustering studies. Selected protein spots with signifi-
cant difference were excised from a preparative gel stained
with CBB G-250 and identified by MALDI MS.
Setting up of preparative 2-D gels for spot picking
For preparative Coomassie brilliant blue (CBB) - stained
gel, 60 μg of each of the 8 protein pools were combined, to
give a total of 480 μg of protein. The volume was adjusted
to 450 μl with the rehydration buffer. The IEF and second
dimension SDS-PAGE were run according to standard pro-
cedures. Gel was fixed in 30% (v/v) ethanol, 2% (v/v) phos-
phoric acid for 30 min with two exchanges of the fixing
solution, washed three times with 2% (v/v) phosphoric acid
for 10 min each, balanced in pre-staining buffer (12% (w/v)
(NH4)2SO4, 2% (v/v) phosphoric acid, 18% (v/v) ethanol)
for another 30 min and stained in staining solution (0.01%
(w/v) CBB G-250, 12% (w/v) (NH4)2SO4, 2% (v/v) phos-
phoric acid, 18% (v/v) ethanol) for 72 h. The gel was stored
in the staining solution until the spots of interests were
manually picked.
Mass spectrometry: in-gel tryptic digestion and identification
In-gel digestion was carried out manually with trypsin.
Spots were first destained twice with a mixture of 50%(v/v) ACN for 15 min each and than once with 100 mM
NH4HCO3 and 50% (v/v) ACN for 15 min. Spots were
dried in vacuum centrifuge and then reduced with
100 mM NH4HCO3 containing 10 mM DTT for 45 min
at 56°C, and then alkylated with 54 mM iodoacetamide
in 100 mM NH4HCO3 for 30 min in the dark, at room
temperature. Gels pieces were washed with 100 mM
NH4HCO3, shrunk with 50% ACN for 15 min and dried
in a vacuum centrifuge. Gel particles were rehydrated
with 20 μl of 0.01 μg/μl trypsin proteomics grade (Roche
Diagnostics GmbH) in digestion buffer (95% 50 mM
NH4HCO3/5% ACN) for 45 min at room temperature.
The remaining enzyme supernatant was replaced with
one gel volume of the digestion buffer and digestion was
carried out at 37°C, overnight. After digestion, peptides
were collected in a separate tube, extracted once with
20 μl of 50% ACN and twice with a mixture of 50%
ACN/5% formic acid, dried in a vacuum centrifuge and
reconstituted in 10 μl of 0.1% TFA.
For MS analysis, peptides were purified using ZipTipC18
(Millipore Corporation) following the manufacturer’s
instructions and eluted in 2–3 μl of CHCA (4 mg/ml in
50% ACN/0.1% TFA) directly onto a MALDI target plate
(Shimadzu Biotech Kratos Analytical). Droplets were
allowed to dry at room temperature. Samples analysis was
performed using AXIMA Performance MALDI-TOF-TOF
mass spectrometer (Shimadzu Biotech Kratos Analytical).
Spectra acquisition and processing was performed using
the MALDI-MS software (Shimadzu Biotech Kratos
Analytical) version 2.9.3.20110624 in positive reflectron
mode at mass range 1–5000 Da with a low mass gate at
500 Da and pulsed extraction optimized at 2300 Da. Exter-
nal calibration was performed based on monoisotopic
values of five well-defined peptides: Bradykinin fragment
1–5, Angiotensin II human, Glu1-Fibrinopeptide B human,
Adrenocorticotropic Hormone Fragment 1–17 human and
Adrenocorticotropic Hormone Fragment 7–38 human
(Sigma-Aldrich). External calibration mix (500 fmol/μl) was
diluted with the matrix in ratio 1:1 and applied onto the
MALDI target plate at final concentration of 250 fmol per
spot. Each mass spectrum was acquired by 500 laser
profiles (five pulses per profile) collected across the
whole sample.
After filtering tryptic-, keratin- and matrix-contaminant
peaks, the resulting monoisotopic list of m/z values was
submitted to the search engine MASCOT (version 2.4.01,
MatrixScience, UK) searching all human proteins and
sequence information from Swiss-Prot (version 2014_05,
20265 sequences) and NCBInr (version 20140323, 276505
sequences). The following search parameters were
applied: fixed modification-carbamidomethylation, vari-
able modifications-methionine oxidation and N-terminal
acetylation. Up to 1 missed tryptic cleavage was permitted
and a peptide mass tolerance of ±0.40 Da was used for all
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Mascot score greater than 56, above the significance level
(p < 0.05). The reported proteins were always those with
the highest number of peptide matches.
Quantitative determination of selected proteins in urine
The concentrations of Serotransferrin, α1- antitrypsin, α1-
microglobulin/bikunin, Apolipoprotein A-I and Haptoglo-
bin in urine were measured by immunoturbidimetry using
COBAS Integra 400 Plus (Roche Diagnostics). The kits
used for measurement of these proteins in urine and detec-
tion limits were as follows: Serotransferrin, TQ Transferrin
ver. 2 (Roche Diagnostics) with LOD= 0.013 g/L; α1- anti-
trypsin, TQ a-1 Antitrypsin ver. 2 (Roche Diagnostics) with
LOD= 0.2 g/L; α1-microglobulin/ bikunin, TQ a-1 Micro-
globulin Gen. 2 (Roche Diagnostics) with LOD= 5 mg/L;
Apolipoprotein A-I, TQ APO A-1 ver. 2 (Roche Diagnos-
tics) with LOD= 0.2 g/L; Haptoglobin, TQ Haptoglobin
ver. 2 (Roche Diagnostics) with LOD= 0.1 g/L. The level of
creatinine in urine was determined using the Jaffé method
by Crea Jaffe Gen. 2 Urine Kit (Roche Diagnostics) with
0.01 mmol/l limit of detection.
Bioinformatics and statistical analysis of the proteomics data
For an overview of the cellular localization, molecular
function and biological processes in which identified pro-
teins are included in, we used the UniProt Knowledgebase
(UniProtKB) and Gene Ontology (GO) database. Pathway
analysis was carried out for proteins found to be differ-
ently expressed between tumor and control samples using
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems,
USA). Identified proteins were functionally assigned to
canonical pathways and sub sequentially mapped to the
most significant networks generated from previous publi-
cations and public protein interaction databases. A p value
calculated with the right-tailed Fisher’s exact test was used
to yield a network’s score and to rank networks according
to their degree of association with our data set.
The Mann–Whitney U-test was used to analyze the
correlation between the levels of the 3 selected proteins in
urine and the pathological and clinical stage of prostate.
The relative effectiveness of the diagnostic tests was
illustrated by plotting the true-positive (sensitivity) versus
the false-positive (1-specificity) results in receiver operating
characteristic (ROC) curves. ROC curve analyses were
used to define the most optimal diagnostic cutoff as well as
the diagnostic performance given by areas under the
curves (AUC). AUC were compared using a nonparametric
method as described by Bamber [55]. In order to estimate
the combined diagnostic potential of several candidate bio-
markers, logistic regression analyses were performed with
clinical diagnosis (PCa/BPH) as dependent variable and
measurement of the protein concentrations in urine of
selected proteins as independent variables. A confidencelevel of 95% (p < 0.05) was considered significant for all
performed tests. Statistical analyses were performed using
XLSTAT software (ver. 2014.4.06).
Additional files
Additional file 1: Figure S1. Classification of urine proteins with
differential abundance between PCa and BPH. The molecular function,
biological processes in which they are involved, subcellular location and
type of the proteins were assessed by Gene Ontology search. The
numbers represent percentages.
Additional file 2: Logistic regression models and ROC curves of
combinations of TF, AMPB, HP and PSA. The summary of these results
is presented in Table 3.
Additional file 3: Table S1. Clinical information of patients used to
generate urine samples included in the study together with their PSA
levels, histology grading and tumor stage.
Abbreviations
2-D: Two-dimensional; 2-D DIGE: Two-dimensional difference in gel
polyacrylamide gel electrophoresis; ACN: Acetonitrile; AUC: Areas under the
curves; BPH: Benign prostatic hyperplasia; BSA: Bovine serum albumin;
BVA: Biological variation analysis; CHAPS: 3-[(3-Cholamidopropyl)
dimethylammonio-1-propanesulfonate; CBB: Coomassie brilliant blue;
Da: Dalton; DIA: Differential analysis; DTT: Dithiothreitol; GO: Gene ontology;
IAA: 2-Iodoacetamide; IPA: Ingenuity pathways analysis; MALDI-TOF-TOF:
Matrix-assisted laser desorption/ionization-time of flight-time of flight; MS: Mass
spectrometry; PCa: Prostate cancer; PSA: Prostate-specific antigen; ROC: receiver
operating characteristic; SDS: Sodium dodecyl sulfate; SDS-PAGE: Sodium
dodecyl sulfate polyacrylamide gel electrophoresis; TFA: Trifluoroacetic acid;
Tris: Tris(hydroxymethyl)amino.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KD designed the study, participated in the sample selection and preparation,
2-D DIGE experiment, MS identifications, carried out bioinformatics analysis of
the data and wrote the manuscript. SKiprijanovska participated in the sample
preparation, 2-D DIGE experiment and MS identifications. SKomina and GP
carried out the histological evaluation of the prostate tissue samples from the
patients. NCZ carried out the immunoturbidimetry. MP conceived the study
and participated in the design of the experiments. All authors have read and
approved the final manuscript.
Acknowledgements
This work was supported by the funds for Science of the Macedonian
Academy of Sciences and Arts (grant no. 09-114/1, Biomarker detection in
prostate cancer with the use of 2-D DIGE/MALDI-MS technology). We thank
patients for their participation in the study, the medical personal at the
University Clinic for Urology at the University Clinical Centre “Mother
Theresa”, Skopje, Republic of Macedonia, for the collection of urine samples
and Katerina Markovska for technical assistance.
Author details
1Research Centre for Genetic Engineering and Biotechnology “Georgi D Efremov”,
Macedonian Academy of Sciences and Arts, Krste Misirkov 2, 1000 Skopje,
Republic of Macedonia. 2Institute of Pathology, Medical Faculty, University “St. Cyril
and Methodius”, Skopje, Republic of Macedonia. 3Biochemical laboratory, Clinical
Hospital “Acibadem Sistina”, Skopje, Republic of Macedonia.
Received: 3 October 2014 Accepted: 22 December 2014
References
1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al.
Measurement of prostate-specific antigen in serum as a screening test for
prostate cancer. N Engl J Med. 1991;324(17):1156–61.
Davalieva et al. Proteome Science  (2015) 13:2 Page 16 of 172. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch
G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction
of prostate-specific antigen testing. Am J Epidemiol. 2006;164(4):376–84.
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific
antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med.
1987;317(15):909–16.
4. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of
inflammation and benign prostatic hyperplasia on elevated serum prostate
specific antigen levels. The Journal of urology. 1995;154(2 Pt 1):407–13.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL,
et al. Prevalence of prostate cancer among men with a prostate-specific
antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.
6. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate
cancer. Annu Rev Med. 2009;60:139–51.
7. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next
generation of prostate cancer biomarkers. Sci Transl Med. 2012;4
(127):127rv123.
8. Velonas VM, Woo HH, Remedios CG, Assinder SJ. Current status of
biomarkers for prostate cancer. Int J Mol Sci. 2013;14(6):11034–60.
9. Goo YA, Goodlett DR. Advances in proteomic prostate cancer biomarker
discovery. J Proteomics. 2010;73(10):1839–50.
10. Pin E, Fredolini C, Petricoin 3rd EF. The role of proteomics in prostate
cancer research: biomarker discovery and validation. Clin Biochem.
2013;46(6):524–38.
11. Loeb S. Prostate biopsy: a risk-benefit analysis. The Journal of urology.
2010;183(3):852–3.
12. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to
precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs
in the detection and management of early prostate cancer. BJU Int.
2013;112(6):717–28.
13. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G,
et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of
prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a
multicentric European study. Eur Urol. 2013;63(6):986–94.
14. Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, et al. iTRAQ
identification of candidate serum biomarkers associated with metastatic
progression of human prostate cancer. PLoS One. 2012;7(2):e30885.
15. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of
prostate-specific antigen complexed to alpha(2)-macroglobulin in serum
increases the specificity of free to total PSA for prostate cancer. Urology.
2000;56(2):267–72.
16. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, et al.
2D-DIGE as a strategy to identify serum markers for the progression of
prostate cancer. Journal of proteome research. 2009;8(2):942–57.
17. Cima I, Schiess R, Wild P, Kaelin M, Schuffler P, Lange V, et al. Cancer
genetics-guided discovery of serum biomarker signatures for diagnosis and
prognosis of prostate cancer. Proc Natl Acad Sci U S A. 2011;108(8):3342–7.
18. Qingyi Z, Lin Y, Junhong W, Jian S, Weizhou H, Long M, et al. Unfavorable
prognostic value of human PEDF decreased in high-grade prostatic intraepithelial
neoplasia: a differential proteomics approach. Cancer Invest. 2009;27(7):794–801.
19. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis
and prognosis of prostate cancer. Clinical chemistry. 2008;54(12):1951–60.
20. Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of
conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell
lines: discovery and validation of candidate prostate cancer biomarkers.
Journal of proteome research. 2008;7(8):3329–38.
21. Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying
random forests to identify biomarker panels in serum 2D-DIGE data for the
detection and staging of prostate cancer. Journal of proteome research.
2011;10(3):1361–73.
22. Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D,
et al. Annexin A3 in urine: a highly specific noninvasive marker for prostate
cancer early detection. The Journal of urology. 2009;181(1):343–53.
23. Jayapalan JJ, Ng KL, Shuib AS, Razack AH, Hashim OH. Urine of patients with
early prostate cancer contains lower levels of light chain fragments of
inter-alpha-trypsin inhibitor and saposin B but increased expression of an
inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis.
2013;34(11):1663–9.
24. True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, et al.
CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and
could serve as a cancer biomarker. Mod Pathol. 2010;23(10):1346–56.25. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, et al. Proteomic
analysis of voided urine after prostatic massage from patients with prostate
cancer: a pilot study. Urology. 2004;64(6):1238–43.
26. M'Koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, et al.
Detection of pre-neoplastic and neoplastic prostate disease by MALDI
profiling of urine. Biochem Biophys Res Commun. 2007;353(3):829–34.
27. Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2
(EN2): a tumor specific urinary biomarker for the early diagnosis of prostate
cancer. Clinical cancer research: an official journal of the American
Association for Cancer Research. 2011;17(5):1090–8.
28. Kiprijanovska S, Stavridis S, Stankov O, Komina S, Petrusevska G, Polenakovic M,
et al. Mapping and Identification of the Urine Proteome of Prostate Cancer
Patients by 2D PAGE/MS. International Journal of Proteomics. 2014;2014:12.
29. van Dieijen-Visser MP, Hendriks MW, Delaere KP, Gijzen AH, Brombacher PJ.
The diagnostic value of urinary transferrin compared to serum prostatic
specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with
prostatic cancer. Clin Chim Acta. 1988;177(1):77–80.
30. Alaiya AA, Al-Mohanna M, Aslam M, Shinwari Z, Al-Mansouri L, Al-Rodayan
M, et al. Proteomics-based signature for human benign prostate hyperplasia
and prostate adenocarcinoma. Int J Oncol. 2011;38(4):1047–57.
31. Jayapalan JJ, Ng KL, Razack AH, Hashim OH. Identification of potential
complementary serum biomarkers to differentiate prostate cancer from
benign prostatic hyperplasia using gel- and lectin-based proteomics
analyses. Electrophoresis. 2012;33(12):1855–62.
32. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. Urinary glycoprotein
biomarker discovery for bladder cancer detection using LC/MS-MS and
label-free quantification. Clinical cancer research: an official journal of the
American Association for Cancer Research. 2011;17(10):3349–59.
33. Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, et al. Identification
of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled
mass spectrometry and systems biology network platform. PLoS One.
2011;6(2):e16833.
34. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB,
et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation
products test for detection and monitoring of bladder cancer. The Journal
of urology. 1997;158(3 Pt 1):801–5.
35. Li H, Li C, Wu H, Zhang T, Wang J, Wang S, et al. Identification of Apo-A1
as a biomarker for early diagnosis of bladder transitional cell carcinoma.
Proteome Sci. 2011;9(1):21.
36. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, et al.
Serological and proteomic evaluation of antibody responses in the identification
of tumor antigens in renal cell carcinoma. Proteomics. 2003;3(1):45–55.
37. Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, et al. Identification of
candidate prostate cancer biomarkers in prostate needle biopsy specimens
using proteomic analysis. International journal of cancer Journal
international du cancer. 2007;121(12):2596–605.
38. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary protein
biomarker candidates for the accurate detection of prostate cancer among
benign prostatic hyperplasia patients. J Cancer. 2014;5(2):103–14.
39. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and
malignant prostate tissue to identify novel proteins lost in cancer.
The Prostate. 2002;50(1):54–63.
40. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B,
Bascands JL, et al. Urine in clinical proteomics. Molecular & cellular
proteomics: MCP. 2008;7(10):1850–62.
41. Hortin GL, Sviridov D. Diagnostic potential for urinary proteomics.
Pharmacogenomics. 2007;8(3):237–55.
42. Rodriguez-Suarez E, Siwy J, Zurbig P, Mischak H. Urine as a source for
clinical proteome analysis: from discovery to clinical application. Biochimica
et biophysica acta. 2014;1844(5):884–98.
43. Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe JO, Lance RS, et al.
Identification of prostate-enriched proteins by in-depth proteomic analyses
of expressed prostatic secretions in urine. Journal of proteome research.
2012;11(4):2386–96.
44. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, et al.
Discovery and validation of urinary biomarkers for prostate cancer.
Proteomics Clin Appl. 2008;2(4):556–70.
45. Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, et al.
Comprehensive human urine standards for comparability and
standardization in clinical proteome analysis. Proteomics Clin Appl.
2010;4(4):464–78.
Davalieva et al. Proteome Science  (2015) 13:2 Page 17 of 1746. Magdeldin S, Enany S, Yoshida Y, Xu B, Zhang Y, Zureena Z, et al. Basics and
recent advances of two dimensional- polyacrylamide gel electrophoresis.
Clin Proteomics. 2014;11(1):16.
47. Kushner I. Regulation of the acute phase response by cytokines.
Perspect Biol Med. 1993;36(4):611–22.
48. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to
inflammation. N Engl J Med. 1999;340(6):448–54.
49. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and
cell death: Is subcellular localization the answer? Cell Cycle. 2009;8(8):1168–75.
50. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein
kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.
51. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?
Lancet. 2001;357(9255):539–45.
52. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a
confounding factor in cancer biomarker discovery and validation.
Nature reviews Cancer. 2010;10(1):2–3.
53. Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI, Hashim OH. Can the
acute-phase reactant proteins be used as cancer biomarkers? Int J Biol
Markers. 2010;25(1):1–11.
54. Bradford MM. A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Analytical biochemistry. 1976;72:248–54.
55. Bamber D. The area above the ordinal dominance graph and the area
below the receiver operating graph. J Math Psychol. 1975;12:387–415.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
